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Background: Identification of molecular factors involved in artery wall stabilization after extracellular matrix injury
elicited by inflammation and proteolysis has a major role in the development of new therapies for atherosclerosis. A study
from our group demonstrated that endovascular seeding of vascular smooth muscle cells (VSMCs) promotes healing and
stabilizes experimental aneurysms by downregulating matrix metalloproteinase and upregulating tissue inhibitor of
metalloproteinase and collagen gene expression. We analyzed expression of transforming growth factor–beta (TGF-)
and its receptors in experimental aneurysms treated with endovascular VSMC therapy.
Methods and results: Aneurysms were generated in Fischer 344 rats by 14-day orthotopic implantation of a segment of
guinea pig abdominal aorta (xenograft). During an endovascular repeat operation, syngeneic VSMCs were seeded in the
aneurysm, always resulting in aneurysm diameter stabilization after 8 weeks, whereas diameter of control aneurysms
infused with culture medium further increased. Seven days after repeat operation the intima or thrombus was separated
from the aneurysmal wall in the two groups. Reverse transcriptase polymerase chain reaction with the domestic gene 18s
as a standard demonstrated that aneurysm stabilization was associated with a statistically significant increase in TGF-1, but
not TGF-2 or TGF-3, messenger RNA levels in the intima. Enzyme-linked immunosorbent assay demonstrated increased
TGF-1 protein in the aneurysmal wall. mRNA levels of the two serine and threonine kinase TGF- receptors remained
unchanged.
Conclusions: Healing and stabilization of aneurysms with endovascular cell therapy is associated with a specific pattern of
gene expression, resulting in paracrine secretion of TGF-1. Our study provides insight into the molecular mechanisms
of arterial aneurysm healing and stabilization. (J Vasc Surg 2003;37:1301-9.)
Once extracellular matrix injury has started, ongoing
aneurysmal growth can be interpreted as the consequence
of healing failure. In a recent study,1 our group demon-
strated that aneurysmal xenograft healing and stabilization
can be attained with endovascular seeding of vascular
smooth muscle cells (VSMCs). The microscopic appear-
ance of stabilized xenografts suggested to us that the
seeded VSMCs trigger a healing process that interrupts
aneurysmal wall destruction by inflammation and proteol-
ysis and promotes wall reconstruction.1 Most of the bio-
logic changes induced by endovascular VSMC seeding
were observed in the aneurysmal wall itself, whereas the
seeded VSMCs remained localized in the intima. Inward
localization of seeded cells and outward localization of
changes in gene transcription support the view that seeded
cells secrete paracrine factors that diffuse centrifugally to
reach the aneurysm wall and control inflammation, prote-
olysis, and wall reconstruction.
Transforming growth factor–beta (TGF-) belongs to
a family of cytokines with multiple roles in tissue develop-
ment and healing because they modulate inflammation,
proteolysis, extracellular matrix synthesis, cell proliferation,
cell survival, and cell migration.2 TGF- activity is regu-
lated by protein concentration, activation by proteolytic
cleavage,3 and expression of receptors, particularly the type
I and type II serine and threonine protein kinase receptors,
which mediate signal transduction to cell nuclei.4 TGF-1
is expressed by VSMCs in the normal artery wall,5 and its
production is increased during artery wall repair after me-
chanical injury.6 Among three identified isoforms, TGF-1
and TGF-2 are involved in healing of cutaneous wounds.
7
In abdominal aortic aneurysm in human beings, TGF-1
may be involved in diameter control through production of
cystatin C, an inhibitor of cysteine proteases such as elastase
cathepsins S and K.8
In the present work we analyzed the expression of the
three isoforms of TGF- and its two serine and threonine
receptors in experimental aneurysms. To address the role of
TGF- in aneurysm growth, we designed a model of al-
ready developed aneurysms in rats, in which aneurysm
From Centre National de la Recherche Scientifique (CNRS) Unite´ Mixte de
Recherche (UMR) 7054, Centre de Recherches Chirurgicales, Universite´
Paris XII, UFR de Me´decine, Hoˆpital Henri Mondor,a Service de Chiru-
rgie Thoracique et Vasculaire, Hoˆpital Tenon,b and Service de Chirurgie
Vasculaire et Endocrinienne, Hoˆpital Henri Mondor.c
Supported by CNRS, La Fondation de l’Avenir pour la Recherche Me´dicale
Applique´e (grant ET9-210) and La Fondation de France. Dr Losy was
supported by a grant from Assistance Publique–Hoˆpitaux de Paris (AP-
HP), Paris, France.
Competition of interest: none.
Reprint requests: Eric Allaire, Centre de Recherches Chirurgicales, 8 rue du
Ge´ne´ral Sarrail, 94010 Cre´teil, France (e-mail: allaire@club-internet.fr).
Copyright © 2003 by The Society for Vascular Surgery and The American




diameter stability was attained with endovascular seeding of
VSMCs. Our results show that healing and stabilization of
already developed aneurysms is associated with a transient
increase in TGF-1 expression. We report the first identifi-
cation of a molecule potentially involved in functional
healing of already developed experimental aneurysms.
MATERIAL AND METHODS
Animals and surgery. Animals housed and cared for
according to European Union Standards received analgesia
and were anesthetized with 5 mg/100 g body weight of
pentobarbital administered intraperitoneally. Hartley
guinea pig (Iffa Credo, Lyon, France) abdominal aortas
were decellularized with sodium dodecylsulfate, as de-
scribed.9 The tube of arterial extracellular matrix obtained
with this method was grafted orthotopically into male
Fischer 344 rats (n 50; Iffa Credo) during a first surgical
procedure.
Syngeneic male Fischer 344 rat VSMCs were isolated
from thoracic aortas10 and were grown in RPMI 1640 and
medium 199, with L-glutamine and 10% fetal calf serum
(FCS; Gibco-BRL, Grand Island, NY). More than 98% of
isolated cells grown to 80% confluence were stained posi-
tively with an anti--actin antibody (Dakopatt, Copenha-
gen, Denmark).
A second surgical procedure was performed 14 days
later, at which time the xenograft diameter had increased
more than 50% to comply with aneurysm definition.11
Graft diameter was measured with a grid in the microscope
eyepiece immediately after transplantation at repeat opera-
tion and before euthanasia at day 7 or week 8 after seed-
ing.12 The aneurysmal xenograft was isolated from blood
flow with clamps after gentle dissection. Its lumen was
gently rinsed with culture medium through a PE10 cathe-
ter introduced at aortotomy performed downstream in the
native aorta (Fig 1, A). Passage five to eight VSMCs were
resuspended in culture medium with 5% FCS injected into
the aneurysmal xenograft lumen (107 cells per xenograft)
and allowed to attach by sedimentation during four 90-
degree rotations (sedimentation duration 2 minutes for
each position) for 8 minutes. Previous studies with PKH26
fluorescent dye staining in vivo assessed VSMC intimal
location after seeding (data not shown). As control, aneu-
rysmal xenografts were infused with culture medium with
5% FCS without cells. Diameter increase was calculated as:
(Diameter at harvest  Diameter at seeding)/Diameter at
seeding.
Analysis of mRNA content. TGF-1, TGF-2, TGF-
3, and TR I and TR II messenger RNA levels were
analyzed with reverse transcriptase polymerase chain reac-
Fig 1. Aneurysm healing and stabilization with endovascular VSMC therapy. A, Schema of endovascular infusion in
experimental aneurysms attained with 14-day implantation of an aortic xenograft. B, Macroscopic results show
stabilization of diameter of aneurysms after VSMC endovascular seeding. C, VSMC staining with anti--actin antibody
on cryostatic cross-sections of control (top) and VSMC-seeded (bottom) aneurysms 7 days after endovascular repeat
operation. Dashed white line shows separation of tissues during microdissection, enabling separate analysis with
RT-PCR and ELISA. Black bar shows media and adventitia thickness. White bar shows intima composed mainly of
VSMCs in VSMC-seeded vessels. Th, Thrombus. D, Microscopic appearance of aneurysms 8 weeks after endovascular
repeat operation shows a dense collagen network in VSMC-seeded aneurysms (bottom) in comparison with control
aneurysms (top). Original magnification 20. *P  .05; **P  .01.
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tion (RT-PCR), and compared to the RNA level of domes-
tic gene 18s (Quantum RNA 18s Internal Standards kit;
Ambion, Montrouge, France). Intima or thrombus, and
media plus adventitia (Fig 1, C) were separated with micro-
dissection and pooled by layers and groups. Total RNA was
extracted with TRIzol (Life Technologies, Rockville, Md)
and treated with grade I deoxyribonuclease (DNAse;
Roche Molecular Biomedicals). RNA was extracted accord-
ing the same protocol from VSMCs in culture and from
normal Fischer 344 rat aorta. RT was performed with
random primers, and Superscript II (Life Technologies),
deoxyribonucleoside triphosphate (dNTP), dithiothreitol,
and ribonuclease inhibitor (Roche Molecular Biochemi-
cals). PCR was performed in a PCR Express thermocycler
(Hy baid, Ashford, UK) in the same tube for both the gene
of interest (primers: matrix metalloproteinase (MMP)–2;
TGF-1, 5'-CG GACTAC TACGCCAAAGAA-3'/5'-
TCAAAAGACAGCCACTCAGG-3'; TGF-2, 5' CCG
CCC ACT TTC TAC AGA CCC 3'/5' GCG CTG GGT
GGG AGA TGT TAA 3'; TGF-3, 5' TGC CCA ACC
CGA GCT CTA AGC G 3'/ 5' CCT TTG AAT TTG ATC
TCC A 3'; TR I, 5'-ACGTTCATGGTTCCGAGAGG-3'/
5'-TCG CAAAGCTGTCAGCCTAG-3'; TR II, 5'-AAGT
CTTGCATGAGCAACTGC-3'/5'-GATGTCAGAGAAGA
TGTCC3') (Genset Oligos SA, Paris, France) and 18s. Final
PCR conditions were chosen to prevent interference between
the two sets of primers. The PCR mix contained Taq poly-
merase (EurobioTaq; Eurobio, Les Ulis, France) in buffer,
dNTP, and magnesium chloride. Negative control assays were
performed without Superscript II. Ten microliters of PCR
products were run in 2% agarose gel with 5 g/mL of
ethidium bromide, visualized under untraviolet light with a
video camera. Bands of amplified sequences corresponding to
the gene of interest and to 18s were quantified with Gel
Analyst (Iconix). Results were expressed as a ratio between
signals corresponding to the gene of interest and 18s.
ELISA for TGF-1. The sandwich enzyme-linked
immunosorbent assay (ELISA; Promega, Madison, Wis)
recognizes active, not latent, TGF-1. Quantification was
performed according to manufacturer instructions, either
after Triton extraction for active form quantification or
after acid and ethanol extraction and activation for total
TGF-1 quantification.
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Histologic analysis and immunohistochemistry.
Cryostat cross sections (5 m) were made from the center
of the aneurysmal xenografts. Collagen was evidenced with
sirius red staining. Primary antibody for -actin was a
mouse monoclonal antibody (Dakopatt), with an alkaline
phosphatase–anti-alkaline phosphatase technique (Dako-
patt). The anti-TGF-1 polyclonal antibody raised in rab-
bits was a generous gift from Dr Saez.14 The secondary
antibody was a goat anti-rabbit antibody with 3,3'-diami-
nobenzidine tetrahydrochloride. Control sections were
generated by omission of the primary antibody.
Statistical analysis. Results are expressed as mean 	
SD. Comparisons between two groups were done with the
nonparametric Mann-Whitney U test (Statview, version
4.5).
RESULTS
Aneurysm diameter and microscopic appearance
VSMC seeding consistently resulted in stabilization of
diameter of aneurysmal xenografts.1 Conversely, infusion
of culture medium was always followed by a statistically
significant increase in aneurysm diameter after 2 months
(Fig 1, B). Immunohistochemistry 7 days after endovascu-
lar VSMC seeding disclosed a thick intima in aneurysmal
xenografts, composed mainly of -actin–positive cells,
whereas thrombus covered the luminal aspect of control
aneurysmal xenografts (Fig 1, C). In VSMC-seeded aneu-
rysms a dense network of collagen developed in the intima
and adventitia (Fig 1, D).
Expression of TGF- and its receptors in VSMCs in
culture and in experimental aneurysms
For all molecules tested, mRNA was detected in cul-
tured cells and in aneurysmal xenografts after 14-day im-
plantation (Fig 2). TGF-2 and TGF-3 were upregulated
in aneurysmal xenografts before endovascular infusion.
Conversely, TGF-1 mRNA levels remained low in the
intima and in the media and adventitia (ie, in the aneurys-
mal wall itself) but were high in VSMCs in culture. Com-
parison of TGF-1 mRNA level between native aorta and
VSMCs in culture demonstrated that the in vitro phase of
VSMCs culture doubled TGF-1 mRNA content.
TGF- expression after VSMC therapy
TGF- isoform mRNA content. mRNA content en-
coding for the three isoforms of TGF- was measured 7
days after endovascular reoperation. In the intima or
thrombus, TGF-1 mRNA level was higher in the seeded
vessels, whereas TGF-2 and TGF-3 mRNA level was
similar in the two groups (Table I). In the media plus
adventitia, TGF-1 mRNA was increased in the seeded
vessels in comparison with control nonseeded vessels, with-
out reaching a statistically significant difference. TGF-2
and TGF-3 mRNA content was not modulated with
VSMC seeding (Table I).
Kinetics of TGF- mRNA content variations after
endovascular VSMC seeding. In aortas harvested 3 and 7
days after endovascular repeat operation, the intima or
thrombus and the media plus adventitia were easily sepa-
rated with microdissection, enabling separate mRNA ex-
traction of the two layers in the two groups. In VSMC-
seeded aortas harvested at 8 weeks the intima could not be
separated from the media plus adventitia. Therefore mRNA
analysis at this time was performed from the whole aortic
wall in the two groups. As observed at day 7, TGF-1
mRNA content at day 3 was increased in the intima but not
in the media plus adventitia after endovascular VSMC
seeding. At 8 weeks TGF-1 mRNA content was similar in
the two groups (Table II). TGF-2 and TGF-3 mRNA
content was similar in the two groups 8 weeks after seeding
(data not shown).
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TGF-1 protein expression after VSMC therapy
Protein quantification at ELISA. ELISA performed
after acid and ethanol extraction was used to measure total,
ie, active and latent, TGF-1. Concordant with mRNA
levels, total TGF-1 protein was increased in the intima of
aneurysmal xenografts 7 days after endovascular seeding,
compared with TGF-1 protein in the thrombus of control
xenografts 7 days after repeat operation (45.4 	 9.7
ng/mg in control xenografts, 144.3 	 30.6 ng/mg in
seeded aneurysmal xenografts; P  .05). In the media plus
adventitia, TGF-1 protein was also increased after endo-
vascular VSMC seeding (124.6 	 5.8 vs 162.9 	 12.2
ng/mg in control and seeded aneurysmal xenografts, re-
spectively; P  .05) (Fig 3, A).
ELISA performed after extraction with Triton was used
to measure active TGF-1. In VSMCs in culture and in
normal rat aorta the percentage of active over total TGF-1
was low (Fig 3, B). In aneurysmal xenografts just before
endovascular repeat operation this percentage was dramat-
ically increased. After endovascular repeat operation and
endoluminal infusion, the percentage of active TGF-1 fell
to low levels in the intima or thrombus but remained high
in the media and adventitia (Fig 3, C).
Immunohistochemistry. Immunohistochemistry
with anti-TGF-1 antibody evidenced few positive cells in
the luminal thrombus and in the medial and adventitial
layers 7 days after endoluminal injection of culture medium
in the control group. Conversely in the aneurysms 7 days
after endoluminal seeding of VSMCs, numerous cells in the
intima were strongly positive for anti-TGF-1 staining (Fig
4). Omission of the primary antibody suppressed cell and
extracellular matrix staining (data not shown).
TGF- receptor expression after VSMC therapy
RT-PCR did not evidence significant differences in TR
I and TR II mRNA ratio to 18s mRNA levels 7 days after
endovascular repeat operation (Intima: TR I, 0.51 	 0.51
vs 0.86	 0.37 [P .123, Mann-Whitney U test]); TR II,
0.39 	 0.25 vs 0.76 	 0.35 [P  .275, in aneurysms with
no VSMC vs aneurysms with VSMC seeding]. Media plus
adventitia: TR I, 0.92 	 0.56 vs 1.47 	 1.45 [P  .827];
TR II, 0.52	 0.36 vs 0.73	 0.64 [P .827, in aneurysms
with no VSMC vs aneurysms with VSMC seeding]).
DISCUSSION
Identification of molecular factors promoting artery
wall stabilization after extracellular matrix injury elicited
with inflammation and proteolysis is a major issue for new
therapies for atherosclerosis.15-19 In vivo manipulations of
Fig 2. mRNA content in comparison to 18s of TGF- and receptors. Culture of VSMCs strongly induces members
of TGF- in comparison with normal rat aorta. TGF-1 mRNA levels are low in 14-day experimental aneurysms.
mRNA levels of constitutive MMP-2 are shown for comparison. Data represent results of RT-PCR performed on pools
of three experimental aneurysms.
Table I. TGF- isoforms 1, 2, and 3 mRNA content in




VSMC  0.73 	 0.10 0.52 	 0.58 0.74 	 0.39
VSMC  1.40 	 0.36 0.67 	 0.23 0.69 	 0.08
P .049 .827 .513
Media  adventitia
VSMC  0.89 	 0.04 0.10 	 0.04 0.25 	 0.25
VSMC  1.62 	 0.88 0.11 	 0.10 0.16 	 0.04
P .083 .999 .563
Data represent measurements from three pools of three grafts.
VSMC, Vascular smooth muscle cell; , negative; , positive.
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arteries constantly resulting in wall stability or instability
enable development of predictive biology because tissue
analysis can be performed before major wall remodeling
occurs. VSMC endovascular seeding in already formed
aneurysms offers a unique opportunity to understand
which cellular and molecular mechanisms may trigger an-
eurysm stabilization and healing. Our data demonstrate a
correlation between TGF-1 and aneurysm stabilization,
with TGF-1 expression electively increased in aneurysmal
aortic xenografts after VSMC endovascular seeding leading
to control of diameter, a decisional clinical end point for
aortic aneurysms.20 Most TGF-1 appears to be synthe-
sized in the intimal layer where VSMCs have been seeded,
whereas the level of activated protein is increased in the
Fig 3. TGF-1 protein content measured with ELISA. A, Seven days after endovascular repeat operation, VSMC
seeding is followed by a significant increase in total (latent plus activated) TGF-1, both in the intima and the aneurysm
wall. B, Whereas TGF-1 is mostly in its nonactivated form in cultured VSMCs and normal rat aorta, activated TGF-1
is the predominant form of TGF-1 in the inflammatory context of aneurysms. C, Seven days after endovascular repeat
operation, TGF-1 is mostly in its activated form in the aneurysmal wall in both groups. Values for total TGF-1 are the
average of three measurements on three different grafts in each group. Values for active TGF-1 obtained by pooling
values for three grafts. *P  .05, Mann- Whitney U test.
Table II. Kinetics of TGF-1 mRNA content evolution in aneurysmal xenografts after endovascular repeat operation
(TGF-1/18s ratio); pools of three grafts.
Day 14  3 Day 14  7 Day 14  8 wk
Intima
VSMC  0.61 	 0.13 0.73 	 0.10
VSMC  1.26 	 0.43 1.40 	 0.36 VSMC  0.84 	 0.32
P .049 .049 VSMC  0.96 	 0.15
Media  adventitia
VSMC  0.72 	 0.26 0.89 	 0.04
VSMC  0.43 	 0.31 1.62 	 0.88
P .127 .083 .999
Data represent measurements from three pools.
VSMC, Vascular smooth muscle cell; , negative; , positive.
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entire wall thickness of the VSMC-treated aneurysm. The
increase in TGF-1 mRNA is transient, and disappears 2
months after cell therapy. Since TR I and TR II are ex-
pressed in aneurysmal xenografts, we provide strong evi-
dence that TGF-1 is a paracrine factor secreted at the
initial phase of aneurysmal xenograft stabilization attained
with endovascular VSMC therapy. Differences between
groups for TGF-1 expression are related to differences in
the most endoluminal layer of the wall, ie, thrombus versus
intimal accumulation of VSMCs.
In our study, TFG-1 mRNA levels exceeded levels of
the two other isoforms in VSMCs in vitro before seeding
and in aneurysmal xenografts in vivo after VSMC seeding.
Moreover, among the three isoforms of TGF-, only
TGF-1 mRNA levels were correlated with aneurysmal
xenograft stabilization with endovascular VSMC therapy.
In atherosclerotic lesions in human beings, Bobik et al5
observed a correlation between atherosclerosis severity and
expression of TGF-1 but not TGF-3. Whereas TGF-1
gene polymorphism is associated with severity of coronary
disease after heart transplantation,21 the polymorphism of
TGF-2 does not influence early ischemic heart disease.
22
Involvement of TGF-1 in structural changes in arteries in
adults is further suggested by the efficiency of TGF-1
overexpression in changing normal wall structure23,24 and
is now evidenced in the setting of experimental aneurysm
expansion and healing.
Most TGF-1 isolated in aneurysmal xenografts before
and after endovascular repeat operation was the active
form. Our data also show that in the normal aortic wall and
in cultured cells, TGF-1 mostly is in its inactive proform.
MMP-2, MMP-9,25 and plasmin26 can activate latent
TGF-1. We have shown previously that MMP-2 and
MMP-9 are upregulated in aneurysmal xenografts12 and
that the plasmin pathway is strongly stimulated in and is
essential to aneurysmal degeneration of aortic xenografts.27
In normal rat aorta and in VSMCs in culture, MMP-2 is
inactive and MMP-9 is not expressed. This suggests that
activation of TGF-1 is triggered by the proteolytic context
of xenograft aneurysmal degeneration and expansion. Sta-
bilization with endovascular VSMC seeding is associated
with both an increase in total TGF-1 and a high propor-
tion of activated TGF-1 in the aneurysmal wall.
After release and activation by proteolytic cleavage,
TGF-1 activity in tissues is conditioned by local expression
of receptors. Among TGF- receptors identified on the
basis of their affinity for TGF- family members, TR I and
TR II in particular have a cytoplasmic domain with serine
Fig 4. TGF-1 immunostaining of aneurysms 7 days after endovascular repeat operation. In the control group
(VSMC-), few TGF-1–positive cells (long arrows) are observed, either in luminal thrombus or adventitia. In
VSMC-seeded vessels, numerous cells stained with anti-TGF-1 antibody, mainly in the intima. In both groups, patchy
areas of extracellular matrix stained with anti-TGF-1 antibody (open arrow). L, Lumen.
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and threonine kinase activity and signal to cell nucleus
through the Smad cascade.4,28 Our results suggest that
aneurysmal xenografts express these receptors and there-
fore can respond to TGF-. TR I and TR II expression was
not modified at mRNA level by VSMC endovascular seed-
ing, demonstrating that TGF-1 expression is the only
member of TGF family and receptors induced with cell
therapy.
Data from the present study demonstrate that the bulk
of TGF-1 is synthesized in the intima, where VSMCs have
been seeded, whereas TGF-1 protein is distributed
throughout the aneurysm wall after seeding. These diver-
gent localizations of synthesis and location of protein in the
wall suggest that TGF-1 is an intimal paracrine factor that
diffuses centrifugally to the aneurysmal lesion. The healing
process leading to aneurysmal xenograft stabilization with
endovascular seeding of VSMCs is initiated by changes in
the aneurysm itself: reduced content in mRNA encoding
for MMP-1, MMP-3, MMP-9, and MMP-12 and in-
creased content in tissue inhibitor metalloproteinase
(TIMP)–1, TIMP-3, and collagen types I and III mRNA.1
TGF-1 exerts paracrine control on gene expression in
cells.29 Under defined experimental conditions, TGF-1
shifts the MMP-dependant proteolytic balance toward in-
hibition by downregulating expression of various MMPs
and upregulating TIMP expression at mRNA levels.30,31 As
another contribution to proteolysis regulation, TGF-1
induces plasminogen-activator inhibitor (PAI)–1 expres-
sion.32 PAI-1 overexpression suppresses aneurysmal de-
generation in the xenograft model by inhibiting MMP-9
activation.27 Apart from decreasing proteolysis, TGF-1
increases collagen production in various cell types, includ-
ing fibroblasts and VSMCs,33 and lysyl oxidase critical for
collagen cross-linking and organization into fibers.34
TGF-1 is induced during healing after arterial balloon
injury, and its perfusion stimulates VSMC proliferation in
balloon-injured rat carotid arteries.6 Taken together, these
data designate TGF-1 as a paracrine factor mediating
decreased wall destruction and increased wall reconstruc-
tion after endovascular VSMC seeding in aneurysmal xeno-
grafts.
Since many cell types respond to stress by increasing
TGF-1 synthesis, and since TGF-1 may exert opposite
effects depending on cell phenotype, clarifying the role of
TGF-1 in arterial stability is not easy.
35 In nonseeded
aneurysmal xenografts, sources of TGF-1 may be acti-
vated inflammatory cells, as observed in atherosclerotic
lesions in human beings5,36 and in allograft arteriosclero-
sis.37 The luminal thrombus observed in aneurysmal xeno-
grafts may also provide TGF-1 through platelet recruit-
ment and degranulation.38 After endoluminal seeding, a
thick intimal layer mainly composed of VSMCs develops,
with scattered monocytes and macrophages. We cannot
rule out a possible role of VSMC–inflammatory cell cross-
talk in regulation of TGF-1 production or activation
within the intima. However, the bulk of mRNA extracted
from this neointima is derived from VSMCs, the main cell
type in this layer. Hence VSMCs accumulating after endo-
vascular seeding appear to be the main source of TGF-1.
The healing process leading to aneurysmal xenograft stabi-
lization with endovascular seeding of VSMCs is associated
with induction of TIMP-1 and TIMP-3, collagen types I
and III in the intima.14 TGF-1 exerts autocrine control of
gene expression in cells.39 In addition to exerting a para-
crine effect in the aneurysmal wall, TGF1 may participate
in endovascular aortic reconstruction after VSMC endovas-
cular seeding.
VSMC stress may be an important determinant of
TGF-1 induction in our study. Isolation and culture
strongly induced TGF-1 at the transcriptional level in
VSMCs before seeding, with mostly the inactive proform
being produced. Unlike endovascular prostheses,40 endo-
vascular seeding does not exclude the aneurysmal wall from
arterial hemodynamic radial strain.14 Mechanical strain in-
duces production of TGF-1, and to a lesser extent TGF-
3.
41,42 TGF-1 is responsible for VSMC collagen synthe-
sis in response to sustained mechanical strain.42,43 By
reestablishing a significant population of VSMCs in the
wall, endovascular seeding may correct aneurysmal wall
healing deficiency by increasing the capability to synthesize
matrix in response to hemodynamical strain through aug-
mented TGF-1 synthesis.
Limitations and perspectives. Involvement of
TGF-1 in atherosclerotic aneurysms in human beings has
not been explored. Aortic aneurysmal degeneration of aor-
tic xenografts reproduces some structural, cellular, and
enzymatic aspects of aneurysms in human beings, ie, exten-
sive injury of the extracellular matrix,9 inflammation in the
media and adventitia,44 depletion in VSMCs,45 luminal
thrombus, adventitial neovessels, and upregulation of
MMPs and enzymes of the plasmin pathway.12,27 Unlike
other animal models, aneurysmal degeneration of aortic
xenografts is slow enough to allow endovascular repeat
operation to stabilize degenerated vessels with severe injury
of the extracellular matrix. Although the origins of aneu-
rysmal degeneration of xenografts and atherosclerotic aor-
tas are clearly different, the terminal cellular and enzymatic
effectors are similar, offering a unique opportunity to test
new therapies using the aneurysmal vessel as a scaffold to
form a new, stable vessel from spontaneously nonhealing
vessels. Whether TGF-1 may downregulate proteolysis
and promote wall reconstruction in aneurysms in human
beings will need to be studied with organ culture.
Our data and those from other groups show that the
increase in TGF-1 levels after VSMC seeding or mechan-
ical stimulation42 is transient. Our results raise the possibil-
ity that short overexpression of TGF-1 may trigger healing
in aneurysmal xenografts. We are developing a gene
transfer approach to evaluate the effect of TGF-1 over-
expression in an attempt to stabilize aneurysmal xeno-
grafts.
We thank P. Druelle, J. Magnard, and P. Mario for
animal care; A. Maurette and N. Sauvant for administrative
and secretarial assistance; and Doctor J. Saez, INSERM
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